Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study-Reference-Cited by-同舟云学术

Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study

Published:2015-12 Issue:8 Volume:18 Page:1057-1062
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Gagne Joshua J.,Najafzadeh Mehdi,Choudhry Niteesh K.,Bykov Katsiaryna,Kahler Kristijan H.,Martin Diane,Rogers James R.,Schneeweiss Sebastian

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference22 articles.

1. Availability of comparative efficacy data at the time of drug approval in the United States;Goldberg;JAMA,2011

2. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development;Schneeweiss;Clin Pharmacol Ther,2011

3. Payers step in with ‘real-world’ comparative effectiveness research. MediMedia USA, 2011. Available from: http://www.managedcaremag.com/archives/1106/1106.cer.html. [Accessed October 6, 2014].

4. You can observe a lot (about medical products) by watching (those who use them);Gagne;Epidemiology,2013

5. Design considerations in an active medical product safety monitoring system;Gagne;Pharmacoepidemiol Drug Saf,2012

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methodological guidelines and publications of benefit–risk assessment for health technology assessment: a scoping review;BMJ Open;2024-06

2. Sequential surveillance for drug safety in a regulatory environment;Pharmacoepidemiology and Drug Safety;2018-03-05

3. Selecting and Integrating Data Sources in Benefit–Risk Assessment: Considerations and Future Directions;Statistics in Biopharmaceutical Research;2016-08-31

4. Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care Data;Value in Health;2015-12